At GTC Berlin in October 2026, Nvidia announced that companies including Biolevate, Boltz, and Automata are using its BioNeMo platform to develop scientific agents connecting drug design and lab workflows.

Autonomous systems that use large language models to plan, reason, and take actions — including browsing the web, writing code, calling APIs, and completing multi-step tasks with minimal human intervention.